BioCity's SC0062 gains NMPA breakthrough therapy designation
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second breakthrough therapy designation (BTD).
This new designation is intended to treat diabetic kidney disease (DKD) with albuminuria and highlights the therapy's potential for chronic kidney disease indications.
The BTD was supported by data from the DKD cohort of the Phase II 2-SUCCEED trial, and SC0062 showed major reductions in albuminuria at the 20mg dose against placebo.
The safety profile was favourable both as monotherapy and when combined with treatments such as SGLT2 inhibitors, GLP-1 receptor agonists, RAAS inhibitors, insulin and Finerenone.
BioCity co-founder and executive president Dr Ivy Wang stated: 'With over 700 million people affected globally, kidney disease represents one of our greatest unmet medical challenges.
'This dual BTD recognition validates SC0062's potential to redefine treatment paradigms across renal diseases. We're accelerating development to deliver this promising therapy to patients worldwide.'
The completed 2-SUCCEED programme achieved all efficacy and safety endpoints at 12 and 24-week timepoints for both Immunoglobulin A nephropathy (IgAN) and DKD cohorts.
SC0062 may slow CKD progression compared to non-selective treatments while minimising side effects.
Preclinical studies have shown that it significantly improved pathological scores in acute and CKD models.
The therapy has completed Phase I trials, demonstrating good tolerability, safety and pharmacokinetics without signs of fluid retention.
It has now concluded enrolment for both IgAN and DKD cohorts in the Phase II 2-SUCCEED study and the cohorts have met their primary endpoints.
With these developments underway, BioCity is initiating two Phase III clinical trials that include SUCCESS-01 (IgAN) and SUCCESS-02 (CKD).
"BioCity's SC0062 gains NMPA breakthrough therapy designation" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
登入存取你的投資組合
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Ozempic without the side effects? New drug touted as weight loss game changer
There's no doubt that GLP-1 drugs like Ozempic have been revolutionary — not just for people who want to lower their blood sugar and lose weight but for those who want to control other cravings as well. Unfortunately, sometimes these benefits come with unsightly downsides such as tooth decay, a droopy face or mouth, a saggy butt and hair loss. While many of those side effects are due to rapid weight loss — rather than the drugs themselves — the medications are known to cause icky gastrointestinal issues. People on drugs like Ozempic have complained about some unpleasant side effects, including tooth decay, a droopy face or mouth, a saggy butt and hair loss. K KStock – Now, a groundbreaking new drug has shown some of the same promise in melting belly fat — without making your stomach churn. This week in the journal Cell, researchers unveiled a drug — developed by the Sweden biotechnology company Atrogi AB — based on a type of special molecule. While GLP-1s mimic the GLP-1 hormone the body naturally produces after eating to suppress appetite, this new drug activates metabolism in skeletal muscle. In a Phase I clinical trial involving 25 people with Type 2 diabetes and 48 healthy humans, the drug was successful at improving blood sugar levels and weight — without those pesky GLP-1 side effects. Since most GLP-1s are injectables, the fact that this medication comes in tablet form could be groundbreaking to trypanophobes. Since most GLP-1s are injectables, the fact that this medication comes in tablet form could also be groundbreaking to anyone who is afraid of needles. í¢í°í½í íÅí¸í°í¸íâíÅ½í° – 'This drug represents a completely new type of treatment and has the potential to be of great importance for patients with Type 2 diabetes and obesity,' Shane C. Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet in Stockholm, said in a statement. 'Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections.' Wright noted that the drug can be used 'as a stand-alone treatment and in combination with GLP-1 drugs.' This can be a game changer for people who are micro-dosing drugs like Ozempic due to the sky-high costs. It could also be impactful now that the Food and Drug Administration has cracked down on Ozempic copycats, potentially slimming options for consumers who have come to rely on budget-friendly alternatives. Finally, researchers say the drug can boost weight loss without negatively influencing muscle mass or overworking the heart — both crucial longevity markers. 'Our results point to a future where we can improve metabolic health without losing muscle mass,' said Tore Bengtsson, a professor at the Department of Molecular Bioscience at Wenner-Gren Institute in Stockholm. 'Muscles are important in both Type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.'
Yahoo
6 hours ago
- Yahoo
BioCity's SC0062 gains NMPA breakthrough therapy designation
The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted BioCity's endothelin receptor type A (ETA) antagonist, SC0062, a second breakthrough therapy designation (BTD). This new designation is intended to treat diabetic kidney disease (DKD) with albuminuria and highlights the therapy's potential for chronic kidney disease indications. The BTD was supported by data from the DKD cohort of the Phase II 2-SUCCEED trial, and SC0062 showed major reductions in albuminuria at the 20mg dose against placebo. The safety profile was favourable both as monotherapy and when combined with treatments such as SGLT2 inhibitors, GLP-1 receptor agonists, RAAS inhibitors, insulin and Finerenone. BioCity co-founder and executive president Dr Ivy Wang stated: 'With over 700 million people affected globally, kidney disease represents one of our greatest unmet medical challenges. 'This dual BTD recognition validates SC0062's potential to redefine treatment paradigms across renal diseases. We're accelerating development to deliver this promising therapy to patients worldwide.' The completed 2-SUCCEED programme achieved all efficacy and safety endpoints at 12 and 24-week timepoints for both Immunoglobulin A nephropathy (IgAN) and DKD cohorts. SC0062 may slow CKD progression compared to non-selective treatments while minimising side effects. Preclinical studies have shown that it significantly improved pathological scores in acute and CKD models. The therapy has completed Phase I trials, demonstrating good tolerability, safety and pharmacokinetics without signs of fluid retention. It has now concluded enrolment for both IgAN and DKD cohorts in the Phase II 2-SUCCEED study and the cohorts have met their primary endpoints. With these developments underway, BioCity is initiating two Phase III clinical trials that include SUCCESS-01 (IgAN) and SUCCESS-02 (CKD). "BioCity's SC0062 gains NMPA breakthrough therapy designation" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 登入存取你的投資組合
Yahoo
10 hours ago
- Yahoo
Fat jabs taken by millions linked to 560 cases of deadly side effect and 10 deaths
The Medicines and Healthcare products Regulatory Agency (MHRA) has revealed that more than 560 suspected cases of pancreatitis have been linked to GLP-1 drugs. Pancreatitis is inflammation of the pancreas, which can be either acute (sudden and short-term) or chronic (long-term and ongoing). GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, are a class of medications primarily used to treat type 2 diabetes and, increasingly, obesity, such as Mounjaro, Wegovy, and Ozempic. Read more: State pension £11,973 warning to anyone turning 65 soon The UK's medicines regulator has said that since the drugs were approved, 181 cases of pancreatitis have been linked to tirzepatide, the active ingredient in Mounjaro. This includes five deaths. Additionally, 13 cases have been linked to semaglutide, found in Wegovy and Ozempic. One death has been linked here. While another jab, Liraglutide, has been tied to 116 suspected cases and one death. Exenatide has been linked to 101 cases, with three deaths. Dulaglutide and Lixisenatide, on the other hand, have been linked with 63 cases. No known deaths have been associated. Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. "Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. "To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. "Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." Pancreatitis can also be triggered by gallstones or alcohol. Yet, the MHRA believes there could be a genetic link in some patients, with the regulator launching a new study to investigate its findings further.
